Le Lézard
Classified in: Health, Science and technology
Subjects: PER, ACC, SHM

dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2024


KAISERAUGST, Switzerland, and MAASTRICHT, Netherlands, May 7, 2024 /PRNewswire/ -- dsm-firmenich, the leading innovator in nutrition, health, and beauty, announces that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting today, including the Consolidated Financial Statements as well as the Sustainability Report 2023.

dsm-firmenich logo

Key highlights include:

The shareholders in attendance, together with the votes represented by independent proxy, represented 77.78% of shares.

About dsm-firmenich

As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world's growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss-Dutch company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than ?12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to lifetm every day, everywhere, for billions of people.

For more information, please contact:

dsm-firmenich media enquiries: [email protected]

dsm-firmenich investor relations enquiries: [email protected]

Forward-looking statements

This press release may contain forward-looking statements with respect to dsm-firmenich's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

Logo - https://mma.prnewswire.com/media/2071772/dsm_firmenich_Logo.jpg


These press releases may also interest you

at 08:20
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the Alzheimer's Drug Discovery Foundation ("ADDF") has purchased...

at 08:18
KAV Health Group, LLC, a premier provider of comprehensive mental health services, is excited to announce the opening of its new Mental Health Day Treatment Facility at 5563 Far Hills Ave, Dayton.  This program, starting May 1st, 2024, enhances...

at 08:16
Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-course epigenetic editing therapeutics, today announced the appointment of Jenny Marlowe, Ph.D., as the Company's Chief Development Officer. Dr. Marlowe is a seasoned...

at 08:15
PayGround is excited to announce the appointment of Andy Rellihan as its Chief Commercial Officer. The move is part of the company's strategy to accelerate growth and facilitate its expansion within hospitals and health systems. Under Rellihan's...

at 08:15
Coinciding with Motherhood Mental Health Awareness week, Gether is proud to announce its official launch in the United States, presenting a digital solution tailored to drastically reduce the mental load on women. This launch is backed by eye-opening...

at 08:15
What happens when you have cancer, but are allergic to the most effective medication to treat your disease? Approximately 10% of...



News published on and distributed by: